StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $6.36 | $6.21 | -2.36% | 0.3M |
| 05-12 | $6.12 | $6.34 | +3.59% | 0.7M |
| 05-13 | $5.62 | $4.92 | -12.54% | 2.2M |
| 05-14 | $5.06 | $5.18 | +2.37% | 1.2M |
| 05-15 | $5.09 | $5.21 | +2.36% | 0.6M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2022 2022-12-31 | Annual 2021 2021-12-31 |
|---|---|---|---|---|
Revenue | $109.43M | $92.13M | $1.02M | $4.52M |
Operating Income | $11.69M | $-13.71M | $-12.29M | $361.10K |
Net Income | $5.13M | $-20.11M | $-11.44M | $378.08K |
EPS (Diluted) | $0.27 | $-1.10 | $-0.64 | $0.02 |
Total Assets | $176.92M | $171.17M | $134.65M | $140.99M |
Total Liabilities | $48.62M | $54.17M | $8.54M | $9.61M |
Cash & Equivalents | $23.36M | $13.38M | $18.21M | $84.68M |
Free Cash Flow OCF − CapEx | $18.66M | $4.78M | $10.57M | $625.72K |
Shares Outstanding | 18.76M | 18.45M | 18.29M | 17.86M |
OptimizeRx Corp is engaged in the healthcare market in the United States. is a digital healthcare technology company that connects over two million HCPs and millions of their patients through an intelligent technology platform embedded within a proprietary omnichannel network. OptimizeRx helps life sciences organizations engage and support their customers through its combined HCP and DTC marketing strategies.
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.